N-[(2S)-4-[3-(2-aminocyclopropyl)phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide

N-[(2S)-4-[3-(2-aminocyclopropyl)phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide Basic information

Product Name:	N-[(2S)-4-[3-(2-aminocyclopropyl)phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide
Synonyms:	N-[(2S)-4-[3-(2-aminocyclopropyl)phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide;N-((S)-1-(benzylcarbamoyl)-3-(3-(2-aminocyclopropyl)phenoxy)propyl)benzamide;NCL1;CANP3;CANPL3;LGMD2;LGMD2A;p94
CAS:	1196119-03-5
MF:	C27H29N3O3
MW:	443.54
EINECS:
Product Categories:
Mol File:	1196119-03-5.mol

N-[(2S)-4-[3-(2-aminocyclopropyl)phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide Chemical Properties

Boiling point	754.846±60.00 °C(Press: 760.00 Torr)(predicted)
density	1.209±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
pka	12.848±0.46(predicted)

Safety Information

MSDS Information

N-[(2S)-4-[3-(2-aminocyclopropyl)phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide Usage And Synthesis

Uses	NCL1 is a phenylcyclopropylamine (PCPA)-based Lysine-specific demethylase 1 (LSD1) inhibitor. NCL1 selectively inhibits LSD1 in preference to LSD2, with IC50 values of 2.5 and 26 μM for LSD1 and LSD2, respectively[1].
IC 50	LSD1: 2.5 ± 0.5 μM (IC₅₀)
References	[1] Kakizawa T, et al. Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide. Bioorg Med Chem Lett. 2016 Feb 15;26(4):1193-5. DOI:10.1016/j.bmcl.2016.01.036

N-[(2S)-4-[3-(2-aminocyclopropyl)phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide Preparation Products And Raw materials

Tag:N-[(2S)-4-[3-(2-aminocyclopropyl)phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide(1196119-03-5) Related Product Information

Thalidomide-5-O-C14-NH2 hydrochloride N-[(2S)-4-[3-[(1S,2R)-2-Aminocyclopropyl]phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide alpha-RA-F Bz-Tyr-NH2 5-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione Thalidomide-5-O-C8-NH2 hydrochloride

Login